# GAS-LIQUID CHROMATOGRAPHIC STUDIES OF REACTIONS AND STRUCTURAL RELATIONSHIPS OF STEROIDS 

# V. CONCURRENT SUBSTITUTION IN THE PREGNANE SIDE-CHAIN AND POSITION 11* 

FRANTZ A. VANDENHEUVEL<br>Animal Research Institure, Research Branch, Canada Department of Agriculure, Ottawa, Ontario Kl/ A 0C6 (Canada)

(Received August 30th, 1976)

## SUMMARY

Qualitative and quantitative effects of classical reactions on steroids observed by gas-liquid chromatography (GLC) under standardized conditions, including the double internal standard technique, are reported. Simple procedures applicable to nanogram amounts of reactants are described. Reactions studied include the conversion of keto groups to hydroxyl groups by $\mathrm{NaBH}_{4}$, and the removal of the pregnane side-chain with $\mathrm{NaBiO}_{3}$. GLC chromatograms readily provide information on effects on functional groups at positions $3,11,17,20$, and 21 and the retention times of many steroids unavailable from commercial sources. GLC data analysis provides relationships hetween steroid structure and retention time from which methods for the computation of retention times and steroid identification are designed. The accuracy of these methods is demonstrated.

## INTRODUCTION

The fifth in a series of articles ${ }^{1-4}$ dealing with reactions and structurally dependent chromatographic properties of steroids, the present communication concerns groups of steroids which include very important corticosteroid hormones and metabolites. The steroids of concern are related to those dealt with in Part IV ${ }^{4}$. Table II, column 4, shows that at least one gas-liquid chromatographic (GLC) property of $17 \alpha, 21(20)$-steroids is not altered by the introduction of (11) or $11 \beta$, viz., their propensity to decompose under GLC conditions. Thermal stability is observed, however, for all other steroids of these groups, including those with a fully reduced side-chain, the $17 \alpha, 20 \alpha, 21$ - and $17 \beta, 20 \beta, 21$-steroids. Understandably, full reduction of the sidechain will reveal the presence of thermally unstable species. For this and other reasons discussed below, the facile reduction by sodium borohydride (RD) ${ }^{\mathbf{1}}$ is a very important

[^0]tool in detecting, estimating, and identifying the steroids of concern. Hence, results obtained by applying this reaction are fully described in Table $I^{*}$.

In Part IV ${ }^{4}$, a study of $\mathrm{CrO}_{3}$-pyridine reaction with parent steroids substituted in the side-chain had shown that little information useful for the purpose of identification could be derived from the products. Similar results were obtained with the 11 substituted parent compounds. In contrast, sodium bismuthate oxidation ( $\mathrm{NaBiO}_{3}$ ) produced high yields, generally of a single product characteristic of the original steroid ${ }^{5}$.

The present article reports in Table II the results of an extensive investigation of this reaction with all types of steroids substituted in the side-chain, including those not substituted at position 11. The normal products with this last category of steroids are described in Table XIII. GLC data on the normal products of (11)- and $11 \beta$-substituted steroids are given in Tables XIV and XV, respectively.

In Part IV ${ }^{4}$, the normalcy ${ }^{1}$ of retention time $t^{\prime}{ }_{N R}$, of steroids substituted in the side-chain, though not at position 11 , was shown to be a general feature. For these compounds, the $L_{R}$ value expressed by

$$
\begin{equation*}
L_{R}=10^{3} \times \log t_{N R}^{\prime} \tag{1}
\end{equation*}
$$

is the sum of two constants

$$
\begin{equation*}
L_{R}=M_{R}+G_{R} \tag{2}
\end{equation*}
$$

where $G_{R}$ is characteristic of the group to which the steroid belongs, and $M_{R}$ a value characteristic of the structure of ring $A . M_{R}$ values are listed in Table I of ref. 4. Thus the $M_{R}$ value for steroids with the same ring $A$ or $M$-features is identical by definition. Hence the difference $\Delta G_{R}(a, b)$ of the $L_{R}$ values, $L_{R}(a)$ and $L_{R}(b)$, for $M$-corresponding steroids in groups (a) and (b), is given by the difference of the corresponding $\boldsymbol{G}_{R}$ values, as follows from eqn. 2

$$
\begin{equation*}
\Delta G_{R}(\mathrm{a}, \mathrm{~b})=L_{R}(\mathrm{a})-L_{R}(\mathrm{~b})=G_{R}(\mathrm{a})-G_{R}(\mathrm{~b}) \tag{3}
\end{equation*}
$$

As shown in refs. 1-3, deviations of $G_{R}$ indicating oddity occur for certain steroids of the same group as a result of 11 -substitution. However, it was shown also that such deviations are identical in sign and size for $M$-corresponding steroids, and that eqn. 3 , therefore, is still applicable to odd steroids ${ }^{1-4}$. Hence, the $L_{R}$ value of any steroid, $L_{R}$ (a), can be calculated from the known value $L_{R}(b)$ of an $M$-corresponding steroid featuring the same substitution at position 11 by

$$
\begin{equation*}
L_{R}(\mathrm{a})=L_{R}(\mathrm{~b})+\Delta G_{R}(\mathrm{a}, \mathrm{~b}) \tag{4}
\end{equation*}
$$

Here $\Delta G_{R}(a, b)$ is characteristic of groups (a) and (b) and readily calculable by eqn. 3 given any pair of $L_{R}$ values $L_{R}\left(\right.$ a) and $L_{R}$ (b) for $M$-corresponding steroids of these groups (Table XVI).

[^1]The present GLC data on 11 -substituted steroids, together with similar data from Parts $I^{1}, I^{2}$, and $\mathrm{IV}^{4}$, were used to test the accuracy of $L_{R}$ values calculated by eqn. 4 (Table XVIII).

As shown in the discussion, the wide range of applicability and the reliability of this method of calculation thus demonstrated allow the retention time of steroids of given structure to be accurately predicted. The use of this method of calculation, together with the application of selected reactions whose products are characteristic of the given structure therefore permits the unequivocal identification of a steroid to be made even when a sample of the compound is unavailable. The advantages of this novel approach for the systematic analysis of steroids are discussed.

## EXPERIMENTAL

## Reactions

Procedures used for the RD and the trimethylsilyl (TMS) derivatization of hydroxyl groups have been described in detail ${ }^{1}$.

The procedure used for sodium bismuthate $\left(\mathrm{NaBiO}_{3}\right)$ oxidation was as follows: From 0 to $25 \mu \mathrm{~g}$ of steroid were placed in a $1-\mathrm{ml}$ volumetric-flask (Corning tube No. 5640) by adding with a microsyringe the required volume of solution in methanol and evaporating the solvent under nitrogen. To the contents were added successively, $15 \pm 1 \mathrm{mg}$ of $\mathrm{NaBiO}_{3}$ (Analar; BDH, Toronto, Canada), a $1 / 8 \mathrm{in} . \times 1 / 2 \mathrm{in}$. PTFE covered micro-magnet (Fisher No. 9-312-102), and $120 \mu \mathrm{l}$ of $50 \%(\mathrm{w} / \mathrm{v})$ aqueous acetic acid. The tube was placed in a holder over a strong magnetic stirrer (Gyrathron, Bronwill Scientific Model 25210) adjusted to 350 rpm .

The holder consisted of two 10 cm diameter, 20 mm thick disks of styrofoam glued together face to face after one of the disks had been punched with a No. 4 cork borer to produce a series of $8-\mathrm{mm}$ holes right through and 20 mm from its center. Up to ten tubes held in these holes in a vertical position could be processed simultaneously.

After 30 min of stirring at room temperature, $120 \mu \mathrm{l}$ of $25 \%$ aqueous NaOH were added dropwise to the tube, which was stirred for 1 min . Using a 3 cm long bar magnet, the micro-magnet was made to slide up the side to the neck of the tube where it was seized at one end with tweezers, and held just above the mouth of the tube. It was washed in this position with $600 \mu \mathrm{l}$ of benzene added dropwise, the washings being collected in the tube. After 1 min of vigorous stirring with a vortex mixer, the mixture was centrifuged for 1 min . The clear supernatant (solvent) was carefully removed with a $1-\mathrm{ml}$ syringe (point style No. 3, gauge 22 needle). The extraction with $600 \mu \mathrm{l}$ of benzene was repeated three times. The combined extracts ( 2.4 ml ) were brought, either by, dilution or evaporation depending on the concentration, to such a volume that a $50-\mu \mathrm{l}$ sample contained enough material for GLC analysis. The sample was evaporated to dryness under nitrogen and submitted to TMS derivatization.

## Gas-liquid and thin-layer chromatography

Both gas-liquid and thin-layer chromatography (TLC) methods were used as previously described ${ }^{1-4}$. All $t^{\prime}{ }_{N R}$ values were obtained with steroids or steroid mixtures submitted to TMS derivatization.

## DISCUSSION

## Reactions

Reduction by $\mathrm{NaBH}_{4}$. RD is as shown in Table I. The behaviour of steroids substituted at position 11 paralleled that of the parent steroids described in Table II of Part IV ${ }^{4}$. High yields of $20 \alpha$ and $20 \beta$ products giving excellent GLC chromatograms after TMS derivatization were observed even when the original (20)-steroid was thermally unstable and did not give a GLC peak. While the $20 \beta$ product again was the major one in all cases, the $20 \alpha / 20 \beta$ ratios did not differ as sharply among different groups as they did with the corresponding groups of parent steroids ${ }^{4}$. However, the 21-hydroxyl group again reversed the order of appearance of the GLC peaks of the $20 \alpha$ - and $20 \beta$ steroids, as shown by the $t^{\prime}{ }_{N R}$ values listed in Tables V and VI, VIII and IX, and XI and XII.

TABLE I
REDUCTION BY $\mathrm{NaBH}_{4}(2 \mathrm{~h})$ OF 11 -SUBSTITUTED 20-KETONES

| Starting material |  |  |  | Normal product* |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Abbreviation | Source | GLC properties |  | $\begin{aligned} & 20 \alpha / 20 \beta \\ & \text { ratio } \end{aligned}$ | GLC properties |
|  |  | $t_{N R}^{\prime}$ | $L_{R}$ |  |  |
| $5 \beta \mathrm{P} 3 \alpha 17 \alpha(11,20)$ | P6200 | 783 | 2894 | 17/83 | cf. Tables V ( $\beta$ ) |
| $5 \alpha \mathrm{P} 17 \alpha(3,11,20)$ | P4100 | 905 | 2956 | 18/82 | and VI ( $\alpha$ ) |
| $\triangle 5 \mathrm{P} 3 \beta 17 \alpha(11,20)$ | SRC | 989 | 2995 | 17/83 |  |
| $\triangle 4 \mathrm{P} 11 \beta 17 \alpha(3,20)$ | Q1520, SRC | 1417 | 3151 | 19/81 |  |
|  |  |  |  | 18/82 |  |
| $5 a \mathrm{P} 3 \sim 21(11,20)$ | P2200 | 1244 | 3095 | 15/85 | $\begin{aligned} & c f . \text { Tables VIII }(\beta) \\ & \text { and IX }(\alpha) \end{aligned}$ |
| 5 $\beta$ P3 $\alpha 21(11,20$ ) | P6240 | 1178 | 3071 | 13/87 |  |
| 5aP3 $321(11,20$ ) | P2230 | 1648 | 3217 | 13/87 |  |
| 44P21(3,11,20) | Q3690 | 1647 | 3217 | 18/82 |  |
| $5 \beta$ P11 $\beta 21(3,20)$ | P6270 | 1510 | 3179 | 15/85 |  |
| $5 \alpha \mathrm{P} 3 \beta 11 \beta 21(20)$ | P5400 | 2059 | 3314 | 15/85 |  |
| $\Delta 4 \mathrm{P} 11821(3,20)$ | Q1550 | 2250 | 3352 | 15/85 |  |
|  |  |  |  | 15/85 |  |
| 5PP17 $\alpha^{2} 1(3,11,20)$ | P7100 |  | mposes | 23/77 | cf. Tables XI ( $\beta$ ) |
| $5 \beta \mathrm{P} 3 \alpha 17 \alpha 21(11,20)$ | P9550 |  | mposes | 23/77 | and XII ( $\alpha$ ) |
| $5 \alpha \mathrm{P} 3 \beta 17 \alpha 21(11,20)$ | P5200 |  | mposes | 18/82 |  |
| $\triangle 4 \mathrm{P} 17 \alpha 21(3,11,20)$ | Q2500 |  | mposes | 19/82 |  |
| 5 $\beta$ P3 $\alpha 11 \beta 17 \alpha 21(20)$ | $\mathbf{P 9 0 5 0}$ |  | mposes | 17/83 |  |
| $\triangle 5 \mathrm{P} 3 \beta 11 \beta 17 \alpha 21$ (20) | Q5750 |  | mposes | 17/83 |  |
| $\triangle 4 \mathrm{P} 11 \beta 17 \alpha 21(3,20)$ | Q3880 |  | mposes | 20/80 |  |
|  |  |  |  | 20/80 |  |

[^2]MOLE PER CENT COMPOSITION, $C$, AND TOTAL PER CENT RECOVERY, $R$, OF PRODUCTS FROM NaBiO ${ }_{3}$ OXIDATION OF STEROIDS SUBSTITUTED IN THE PREGNANE SIDE-CHAIN

| Starting material* |  |  |  | Normal product** |  |
| :---: | :---: | :---: | :---: | :---: | :---: |
| No. | Abbreviation | Source | GLC properties | $C$ (in brackets) (mole \%) | $R(\%)$ |
| 1 | SpP3a17a20 ${ }^{\text {S }}$ | P9480 | cf. Table VII of rcf. 4 | [0.8] unchanged, [12.7] $5 \beta \mathrm{P} 3 \alpha(20),[21.8] 5 \beta \mathrm{~A} 3 \alpha(17)$, and [64.6] $5 \beta \mathrm{P} 3 \alpha 20 \beta$ | 84 |
| 2 | 5 $\beta$ P $3 \alpha 17 \times 20 \alpha$ | P9450 | cf. Table VIII of ref. 4 | [6] unchanged, [93] $5 \beta \mathrm{~A} 3 \alpha(17)$ | 80 |
| 3 | -SP3p17a20 $\alpha$ | SRC | cf. Table VIII of ref. 4 | [25] unchanged, $[40] \Delta 5 \mathrm{~A} 3 \beta(17)$, [35] 5,6-epoxy-A3 $\beta(17)$ | 65 |
| 4 | $\triangle^{15 P} 3 \beta 17 \alpha 20 \beta$ | Q5890 | cf. Table Vll of ref. 4 | [25.5] unchanged, [35.5] $\triangle 5 \mathrm{~A} 3 \beta(17),[38.5] 5,6$-ероху-A3 $3(17)$ | 70 |
| 5 | $\triangle 4 \mathrm{P} 17 \times 20 \alpha(3)$ | Q1820 | cf. Table VIII of ref. 4 | [25] unchanged, [75] $14 \mathrm{~A}(3,17)$ | 72 |
| 6 | $\triangle 4 \mathrm{P} 17 \times 20 \mathrm{P}(3)$ | Q1850 | cf. Table VII of ref. 4 | [19] unchanged, [81] $14 \mathrm{~A}(3,17)$ | 70 |
| 7 | $5 \beta$ P17 $1721(3,20)$ | P6300 | decomposes | [95] $5 \beta \mathrm{~A}(3,17)$ | 75 |
| 8 | SuP17a21(3,20) | P2320 | decomposes | [97] $5 u A(3,17)$ | 66 |
| 9 | $44 \mathrm{P} 17 \times 21(3,20)$ | Q1610 | decomposes | [97] $\angle 4 A(3,17)$ | 61 |
| 10 | SaP17c20p21 | SRC | cf. Table XII of ref. 4 | [96] $5 \alpha \mathrm{~A}(17)$ | 65 |
| 11 | $\triangle 5 \mathrm{P} 3 \beta 17 a 20421$ | SRC | cf. Table XIII of ref. 4 | [75] $15 \mathrm{~A} 3 \beta(17)$, [25] 5,6-ероху-А3 $\beta$ (17) | 65 |
| 12 | A4P17a20p21(3) | Q4080 | cf. Table XII of ref. 4 | [97] $\triangle 4 \mathrm{~A}(3,17)$ | 49 |
| 13 | $5 a \mathrm{Pl} 7 \alpha(3,11,20)$ | P4100 | cf. Table I | [11] unchanged, [89] $5 \alpha \mathrm{~A}(3,17)$ | 63 |
| 14 | SPP17 $211(3,11,20)$ | P7100 | decomposes | [92] $5 \mathrm{\beta} \mathrm{~A}(3,11,17)$ | 56 |
| 15 |  | P9550 | decomposes | [95] $5 \beta \mathrm{~A} 3 \times(11,17)$ | 59 |
| 16 | SaP3P17a21(11,20) | P5200 | decomposes | [97] $5 \alpha A 3 \beta(11,17)$ | 61 |
| 17 | $\triangle 4 \mathrm{Pl} 7 \alpha 21(3,11,20)$ | Q2500 | decomposes | [97] $44 \mathrm{~A}(3,11,17)$ | 53 |
| 18 | S $\beta$ P $3 \alpha 17 \alpha 20 \beta 21(11)$ | P9200 | cf. Table X | [96] 5 $\mathrm{AA} 3 \alpha(11,17)$ | 67 |
| 19 |  | P9050 | decomposes | [97] 5 $\beta$ A $3 \alpha 11 \beta(17)$ | 68 |
| 20 | $5 u \mathrm{P} 11 \beta 17 \alpha 21(3,20)$ | P5250 | decomposes | [98] $5 \alpha A 11 \beta(3,17)$ | 49 |
| 21 | A5P3 $\beta 11 \beta 17 \alpha 21$ (20) | Q5750 | decomposes | [66] $\triangle 5 \mathrm{~A} 3 \beta 11 \beta(17)$, [27] 5,6-ероху-/15A3 $\beta 11 \beta(17)$ | 48 |
| 22 | 14P11p17 $21(3,20)$ | Q3880 | decomposes | [97] $14 \mathrm{~A} \\| 1 \beta(3,17)$ | 60 |
| 23 | ${ }_{5 \beta} \mathrm{P} 3 \beta 11 / \beta 17 \alpha 20 \beta 21$ | P8620 | cf. Table XI | [96.5] 5 $\beta \mathrm{A} 3 \beta 11 \beta(17),[4.5] 5 \beta \mathrm{P} 3 \beta(11,17)$ | 64 |
| 24 | 5 $\beta \mathrm{P} 3<111 \beta 17 / 20 \beta 21$ | P8590 | cf. Table XI | [85] 5 $\beta \mathrm{A} 3 \alpha 11 \beta(17),[15] 5 \beta \mathrm{~A} 3 a(11,17)$ | 65 |
| 25 | $5 \alpha \mathrm{P} 3 \beta 11 \beta 17 \alpha 20 \beta 21$ | P4350 | cf. 1 able XI | [97] 5 $\alpha \mathrm{A} 3 \beta 11 \beta(17)$ | 70 |
| 26 |  | Q ${ }^{3} 790$ | cf. Table XI | $[96] \triangle 4 A 11 \beta(3,17)$ | 52 |
| 27 | $\Delta 4 \mathrm{P} 11 \beta 17020 \alpha 21(3)$ | Q3760 | $c f$. Table XII | [98] $44 \mathrm{Al1} \beta(3,17)$ | 54 |

[^3]While a complete RD revealed the presence of $17 a 21(20)$-steroids unaccountable by direct GLC (cf. above), (3) and (11) groups were also reduced in the process ${ }^{1-4}$. The products therefore gave a clue as to the presence of substitution at positions 3 and/or 11, but none as to the original nature of these substitutions. This and other structural problems were readily solved by $\mathrm{NaBiO}_{3}$ oxidation.
$\mathrm{NaBiO}_{3}$ oxidation. In 1953, Brooks and Norymberski ${ }^{5}$ showed that $\mathrm{NaBiO}_{3}$ oxidation of steroids substituted in the pregnane side-chain produced high yields of fragments characteristic of their structure and proposed the analysis of these products as a means of estimating these steroids. While the estimation of corticosteroids by quantification of the formaldehyde generated by this reaction has proved reliable ${ }^{6}$, later work by Breuer and Nocke ${ }^{7}$ has revealed complications precluding the use of the 17-ketosteroid products for the quantitative estimation of steroids substituted in the side-chain.

The present, systematic investigation of the reaction products has shown, however, that their analysis by GLC afforded a reliable tool for the identification of the original steroids. Indeed, with the sole exception of $20 \beta$-pregnanetriol (No. 1), all steroids listed in Table II yielded the readily identifiable parent 17-ketoandrostane as a major, if not the sole product of $\mathrm{NaBiO}_{3}$ oxidation which was demonstrable by

TABLE III
VALUES OF $L_{R}$ AND $G_{R}$, AND SOURCES OF STEROIDS OF GROUP P17a20ß(11)

| Steroid |  |  |  |  | Source(s) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| $\boldsymbol{M}$ | Abbreviation | $t_{\text {ikr }}$ | $L_{R}$ | $G_{R}{ }^{*}$ |  |
| I |  | 564 | 2751 | 638** | $\begin{aligned} & \text { Calculated; } L_{R} 5 \beta \mathrm{P} 20 \beta(11)^{* * *}+ \\ & 1 G_{R^{s}} \end{aligned}$ |
| II | $5 \alpha \mathrm{P} 17 \alpha 20 \beta(11)$ | 632 | 2801 | 651 | $\underset{\Delta G^{\xi}}{\text { Calculated; } L_{R} 5 \alpha \operatorname{P20} \beta(11)^{* * *}+}$ |
| III | 5 $\mathrm{PP} 3 \beta 17 \alpha 20 \beta(11)^{\text {( }}$ | 1130 | 3053 | 651 | Calculated; $L_{R} 5 \beta P 3 \beta 20 \beta(11)^{\cdots}+$ $\Delta G_{R}{ }^{5}$ |
| IV | $5 \alpha \mathrm{P} 3 \alpha 17 \alpha 20 \beta(11)$ | 1132 | 3054 | 653 | $\begin{gathered} \text { Calculated; } L_{R} 5 \alpha \mathrm{P} 3 \alpha 20 \beta(11)^{* \cdots}+ \\ \Delta G_{R^{s}} \end{gathered}$ |
| V | 5 3 P17 $208(3,11)$ | 1099 | 3041 | 638** | Calculated; $L_{R} \operatorname{5\beta P20\beta }(3,11)^{\cdots}+$ $A G_{R}{ }^{\text {B }}$ |
| VI | 5 $\beta$ P3 $\alpha 17 \alpha 20 \beta(11)$ | 1114 | 3047 | 626** | $\begin{aligned} & \text { Prepared; } 30 \min \text { RD } \\ & 5 \beta \mathrm{P} 3 \alpha 17 \alpha(11,20) \end{aligned}$ |
| VII | SaP17a208(3,11) | 1250 | 3097 | 644** | Calculated; $L_{R} 5 \alpha \mathrm{P} 20 \beta(3,11)^{* * *}+$ $\Delta G^{8}$ |
| VIII | $\triangle 4 \mathrm{P} 3 \beta 17 \alpha 20 \beta(11)$ | 1321 | 3121 | 638** | Calculated; $L_{R} \Delta 4 \mathrm{P} 3 \beta 20 \beta(11)^{\cdots}+$ $\Delta G_{R^{8}}$ |
| IX | -4P3p17a20 ${ }^{(11)}$ | 1396 | 3145 | 648 | $\begin{aligned} & \text { Prepared; } 30 \min R D \\ & \Delta S P 3 \beta 17 \alpha(11,20) \end{aligned}$ |
| X | $5 \alpha \mathrm{P} 3 \beta 17 \alpha 20 \beta(11)$ | 1459 | 3164 | 658 | $\begin{aligned} & \text { Prepared; } 30 \text { min RD } \\ & 5 a \mathrm{P} 17 a(3,11,20) \end{aligned}$ |
| XI | 44P17a20 $(3,11)$ | 1422 | 3153 | 622** | $\begin{aligned} & \text { Calculated; } L_{R} \Delta 4 \mathrm{P} 20 \beta(3,11)^{* *}+ \\ & \Delta G_{R^{4}} \end{aligned}$ |

[^4]TABLE IV
VALUES OF $L_{R}$ AND $G_{R}$, AND SOURCES OF STEROIDS OF GROUP P17 $\alpha_{2} 0 \alpha(11)$

| Steroid |  |  |  |  | Source(s) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| M | Abbreviation | $t_{N R}^{\prime}$ | $\boldsymbol{L}_{R}$ | $\boldsymbol{G}_{\boldsymbol{R}}{ }^{*}$ |  |
| I | $5 \beta P 17 \alpha 20 \alpha(11)$ | 624 | 2795 | 682** | $\begin{aligned} & \text { Calculated; } L_{R} 5 \beta P 20 \alpha(11)^{* * *}+ \\ & \Delta G_{R}{ }^{s} \end{aligned}$ |
| II | $5 a \mathrm{P} 17 \alpha 20 \alpha(11)$ | 685 | 2836 | 686 | Calculated; $L_{R} 5 \alpha \mathrm{P} 20 \alpha(11)^{* * *}+$ $\Delta G_{R}{ }^{\text { }}$ |
| III | $5 \beta \mathrm{P} 3 \beta 17 \alpha 20 \alpha(11)$ | 1245 | 3095 | 693 | Calculated; $L_{R} 5 \beta$ P3 $\beta 20 \alpha(11)^{* * *}+$ $\Delta G_{R}{ }^{\text {n}}$ |
| IV | $5 \alpha \mathrm{P} 3 \alpha 17 \alpha 20 \alpha(11)$ | 1236 | 3092 | 691 | Calculated; $L_{R} 5 \alpha \mathrm{P} 3 \alpha_{20} 0 \alpha(11)^{* * *}+$ $\Delta G_{R}{ }^{5}$ |
| $V$ | $5 \beta P 17 \alpha 20 \alpha(3,11)$ | 1213 | 3084 | 672** | $\begin{aligned} & \text { Calculated; } L_{R} 5 \beta P 20 \alpha(3,11)^{* * *}+ \\ & \Delta G_{R^{\Sigma}} \end{aligned}$ |
| VI | $5 \beta \mathrm{P} 3 \alpha 17 \alpha 20 \alpha(11)$ | 1239 | 3093 | 672** | Prepared; 30 min RD <br> $5 \beta P 3 \alpha 17 \alpha(11,20)$ |
| VII | $5 \alpha P 17 \alpha 20 \alpha(3,11)$ | 1358 | 3133 | $680^{* *}$ | Calculated; $L_{R} \operatorname{SaP20\alpha (3,11)^{***}+}$ $\Delta G_{R}{ }^{5}$ |
| VIII | 44P3 $\beta 17 \alpha 20 \alpha(11)$ | 1426 | 3154 | 669** | $\begin{aligned} & \text { Calculated; } L_{R}-44 \mathrm{P} 3 \beta 20 \alpha(11)^{* * *}+ \\ & \int G_{R}^{5} \end{aligned}$ |
| IX | $45 \mathrm{P} 3 \beta 17 \alpha 20 \alpha(11)$ | 1518 | 3181 | 684 | Prepared; $\mathbf{3 0} \mathbf{~ m i n ~ R D ~}$ $45 \mathrm{P} 3 \beta 17 \alpha(11,20)$ |
| X | $5 \alpha \mathrm{P} 3 \beta 17 \alpha 20 \alpha(11)$ | 1566 | 3195 | 689 | Prepared; $\mathbf{3 0} \mathrm{min}$ RD <br> $5 \alpha \operatorname{P17\alpha }(3,11,20)$ |
| XI | $\triangle 4 \mathrm{Pl} 17 \alpha 20 \alpha(3,11)$ | 1542 | 3188 | $657 * *$ | Calculated; $L_{R} \mathbf{1 4 P 2 0 \alpha ( 3 , 1 1 ) ^ { * * * } +}$ $A G_{K}{ }^{8}$ |

[^5]GLC. The important point is, of course, that this product possesses all structural features not included in the side-chain of the original steroid. Together with the TLC and GLC data on the original steroid, this information constitutes a basis for unequivocal identification.

The case of $20 \beta$-pregnanetriol which yields the parent $20 \beta$-diol as major product is remarkable. No other triol, nor any of the corresponding (11)- or $11 \beta$-substituted steroids, including the $5 \beta$ P3 $\alpha 20 \beta$ compounds No. 18 and No. 24 showed similar behaviour.

The $\Delta 53 \beta$-steroids, in addition to the normal 17-keto products, yielded important amounts of the corresponding 5,6-epoxy derivatives (cf. compounds Nos. 3, 4, 11, and 21 in Table II) which gave additional evidence for the $45 P 3 \beta$ structure. Remarkably, the $L_{R}$ values of the 17-keto and 5,6-epoxy-17-keto products always differed by $140 \pm 1 L_{R}$ units. Identical 5,6-epoxides were obtained by $\mathrm{NaBiO}_{3}$ oxidation of the $\Delta 53 \beta(17)$-steroids listed in Tables XIII-XV. For example, $90 \%$ of $\Delta 5 A 3 \beta$ (17) was converted under standard conditions to the 5,6-epoxy derivative in 4 h .

While the 21(20)-, 20ק21-, and 20a21-steroids yielded normal GLC peaks (cf. Table I of Part $\mathrm{IV}^{4}$ and the present article), their $\mathrm{NaBiO}_{3}$ oxidation products, as indeed their $\mathrm{CrO}_{3}$ oxidation products ${ }^{4}$ gave no GLC peaks. Presumably the 20-

TABLE V
VALUES OF $L_{R}$ AND $G_{R}$, AND SOURCES OF STEROIDS OF GROUP P11 $17 \alpha_{2} 2 \beta$

| Steroid |  |  |  |  | Source(s) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| M | Abbreviation | $t_{\text {NR }}^{\prime}$ | $L_{R}$ | $G_{R}{ }^{*}$ |  |
| I | $5 \beta \mathrm{PL11} 17 \alpha 20 \beta$ | 650 | 2813 | $700^{*-}$ | Calculated; $L_{R} \operatorname{S\beta P11\beta 20} \beta^{* * *}+$ $\Delta G_{R}{ }^{5}$ |
| II | $5 \alpha \mathrm{P} 11 \beta 17 \alpha 20 \beta$ | 736 | 2867 | 717 | $\begin{aligned} & \text { Calculated; } L_{R} 5 a P 11 \beta 20 \beta^{* * *}+ \\ & \Delta G_{R^{\xi}} \end{aligned}$ |
| III | $5 \beta \mathrm{P} 3 \beta 11 \beta 17 \alpha 20 \beta$ | 1285 | 3109 | 707** | $\begin{aligned} & \text { Calculated; } L_{R} 5 \beta \mathrm{P} 3 \beta 11 \beta 20 \beta^{* * *}+ \\ & \Delta G_{R^{s}} \end{aligned}$ |
| IV | $5 \alpha \mathrm{P} 3 \alpha 11 \beta 17 \alpha 0 \beta$ | 1288 | 3110 | 709** | Calculated; $L_{R} 5 \alpha P 3 \alpha 11 \beta 20 \beta^{* * *}+$ $\Delta G_{R}{ }^{\text {s }}$ |
| V | $5 \beta \mathrm{P} 11 \beta 17 \alpha 20 \beta(3)$ | 1312 | 3118 | 706** | Calculated; $L_{R} 5 \beta P 11 \beta 20 \beta(3)^{* * *}+$ $\Delta G_{R}{ }^{5}$ |
| VI | $5 \beta \mathrm{P} 3 \alpha 11 \beta 17 \alpha 20 \beta$ | 1247 | 3096 | 675** | P8750; prepared 2 h RD P6200; cf. Table I |
| VII | S $\alpha$ P11 $\beta 17 \alpha 20 \beta(3)$ | 1507 | 3178 | 725 | Calculated; $L_{R} 5 \alpha \operatorname{P11} \beta 20 \beta(3)^{* * *}+$ $\Delta G_{R}{ }^{6}$ |
| VIII | $\Delta 4 \mathrm{P} 3 \beta 11 \beta 17 \alpha 20 \beta$ | 1560 | 3193 | 710** |  cf. Table I |
| IX | $\triangle 5 \mathrm{P} 3 \beta 11 \beta 17 \alpha 20 \beta$ | 1656 | 3219 | 722 | Prepared; 2 h RD $45 P 3 \beta 17 \alpha(11,20)$; cf. Table I |
| X | 5 $\alpha$ P3 $1: \beta 17 \alpha 20 \beta$ | 1702 | 3231 | 725 | Prepared; 2 h RD $5 \alpha \operatorname{P17\alpha (3,11,20);~}$ cf. Table I |
| XI | $44 \mathrm{PI} 1 \beta 17 \alpha 20 \beta(3)$ | 1786 | 3252 | 721 | $\begin{aligned} & \text { Calculated; } L_{R} \triangle 4 \text { P1 } 1 \beta 20 \beta(3)^{* * *}+ \\ & \Delta G_{R}{ }^{5} \end{aligned}$ |

[^6]carboxylic acid arising from $21(20)$-steroids ${ }^{5}$ is not extracted from the neutralized reaction mixture and the 17 -aldehydic products from 200321- and 20a21-steroids ${ }^{5}$ would be thermally unstable.

The $21(20)-; 20 \alpha 21-$, and $20 \beta 21$-steroids, therefore, are characterized by the disappearance of their GLC peak after $\mathrm{NaBiO}_{3}$ treatment and the absence of any product demonstrable by GLC. This property confirms a tentative identity based on TLC and GLC data of the original steroid and its RD products.

The characteristic property of $17 \alpha(20)$-steroids is that they are unaffected by $\mathrm{NaBiO}_{3}$ (ref. 5).

Because of appreciable differences in reactivity towards $\mathrm{NaBiO}_{3}$, the standard conditions described above were selected as a satisfactory compromise ensuring good, roughly uniform yields in all cases.

Yields increased for the least reactive, but decreased for the most reactive steroids when the reaction time was extended from 30 min to 45 min , all other conditions remaining as previously described. Beyond 1 h , a general deterioration of recoveries was observed. A time-dependent decrease in recovery was also demonstrable when the oxidation procedure was applied dircetly to the 17 -keto oxidation products listed in Tables XIII-XV. However, because the recoveries of these compounds still

TABLE VI
VALUES OF $L_{R}$ AND $G_{R}$, AND SOURCES OF STEROIDS OF GROUP P11 $\beta 17 \alpha 20 \alpha$

| Steroid |  |  |  |  | Source(s) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| M | Abbreviation | $t_{N R}^{\prime}$ | $G_{R}{ }^{*}$ |  |  |
| I | SPP11 $\beta_{17}$ | 718 | 2856 | $743 * *$ | $\begin{aligned} & \text { Calculated; } L_{R} 5 \beta \mathrm{P} 11 \beta 20 \alpha^{* * *}+ \\ & \Delta G_{R}{ }^{5} \end{aligned}$ |
| II | $5 \alpha \mathrm{P} 11 \beta 17 \alpha{ }^{2} \boldsymbol{\alpha}$ | 800 | 2903 | 753 |  |
| III | $5 \beta \mathrm{P} 3 \beta 11 \beta 17 \alpha 20 \alpha$ | 1413 | 3150 | 732** | Calculated; $L_{R} 5 \beta P 3 \beta 11 \beta 20 \alpha^{* * *}+$ $\Delta G_{R}{ }^{5}$ |
| IV | $5 \mu \mathrm{P} 3 \alpha 11 \beta 17 \alpha 20 \alpha$ | 1409 | 3149 | 748** | $\begin{aligned} & \text { Calculated; } L_{R} 5 \alpha \mathrm{P} 3 \alpha 11 \beta 20 \alpha^{* * *}+ \\ & \Delta G_{R^{s}} \end{aligned}$ |
| V |  | 1452 | 3162 | 750** |  |
| VI | $5 \beta \mathrm{P} 3 \alpha 11 \beta 17 \alpha 20 \alpha$ | 1416 | 3151 | 730** | SRC; prepared 2 h RD P6200; cf. Table I |
| VII | $5 \alpha \mathrm{P} 11 \beta 17 \alpha 20 \alpha(3)$ | 1641 | 3215 | 762 |  |
| VIII | -4P3F11 $\beta 17 \alpha 20 \alpha$ | 1683 | 3226 | $743 * *$ | Prepared; 2 h RD 44 P17 $\alpha 0 \beta(3,11)$; cf. Table I |
| IX | - 5 P3 $\beta 11 \beta 17 \alpha 20 \alpha$ | 1782 | 3251 | 754 | Prepared; 2 h RD 45 P3 $\beta 17 \alpha(11,20)$; cf. Table I |
| X | 5 $\alpha$ P3 $\beta 11 \beta 17 \alpha 20 \alpha$ | 1841 | 3265 | 759 | Prepared; 2 h RD $5 \alpha \operatorname{P17\alpha }(3,11,20)$; cf. Table I |
| XI | $\triangle 4 \mathrm{P} 11 \beta 17 \alpha 20 \alpha(3)$ | 1941 | 3288 | 757 | Calculated; $L_{R} 44 \mathrm{P} 11 \beta 20 \alpha(3)^{* * *}+$ $A G_{R}{ }^{3}$ |

[^7]exceeded $90 \%$ after 30 min , and because at least 3 h of exposure to the reagents was necessary to bring these recoveries down to the levels $R$ listed in Table II, losses indicated by $R$ could not possibly arise exclusively from the degradation and extractive losses of the 17 -keto products. Rather, they resulted mainly from a reaction involving a more reactive precursor of these compounds, possibly through fusion at the level of $\mathbf{C - 1 7}$ of two precursor molecules. The extreme broadness and late emergence of the GLC peak would make a dimer-size compound undetectable in small amounts. The apparent degradation of the 17 -keto compound probably occurs via the formation of this labile precursor from the 17 -keto compound itself. The existence of an equilibrium between precursor and 17-keto compound largely favouring the latter would explain the comparatively slow decrease in recovery observed with the 17 -keto compound as such.

All other conditions being as described above, yields increased markedly when the amount of $\mathrm{NaBiO}_{3}$ was increased up to 10 mg , then slowly up to 15 mg . No further beneficial effect was observed up to 25 mg , possibly because larger quantities of $\mathrm{NaBiO}_{3}$ made stirring and extraction of the reaction mixture less effective. Likewise stirring increased the reaction rate up to $250-300 \mathrm{rpm}$ only.

The effect of varying the acetic acid concentration from 25 to $80 \%$ was not very

TABLE VII
VALUES OF $L_{R}$ AND $G_{R}$, AND SOURCES OF STEROIDS OF GROUP P20p21(11)

| Steroid |  |  |  |  | Source(s) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| M | Abbreviation | $t_{\text {NR }}^{\prime}$ | $L_{R}$ | $\boldsymbol{G}_{\text {R }}{ }^{*}$ |  |
| I | 58P20 211 (11) | 867 | 2938 | 825** | $\begin{aligned} & \text { Calculated; } L_{R} S \beta P 20 \beta(11)^{* *}+ \\ & \Delta G_{R}{ }^{8} \end{aligned}$ |
| II | $5 \alpha \mathrm{P} 20821(11)$ | 973 | 2988 | 838 | ```Calculated; 的 5aP20\beta(11)*** + \DeltaG}\mp@subsup{G}{R}{}\mp@subsup{}{}{8``` |
| III | 5p83p20821(11) | 1738 | 3240 | 838 | Calculated; $L_{R}{ }^{\Delta G^{5}}{ }^{5} \beta \mathrm{P} 3 \beta 20 \beta(11)^{* * *}+$ |
| IV | 5aP3a20821(11) | 1738 | 3240 | 839 | $\begin{aligned} & \text { Prepared; } 30 \mathrm{~min} \text { RD } \\ & \text { 5aP3a21(11,20) } \end{aligned}$ |
| V | 5 $8 \mathrm{P} 20 \beta 21(3,11)$ | 1690 | 3228 | 816** | Calculated; $L_{R} \operatorname{SBP2O}(3,11)^{\cdots}+$ |
| VI | 58P3a20阝21(11) | 1629 | 3212 | 791** | Prepared; 30 min RD 5BP3a21(11,20) |
| VII | S $\underset{\sim}{\mathbf{P} 20 \beta 21(3,11)}$ | 1923 | 3284 | 831** | ```Calculated; L}\mp@subsup{L}{\mathbf{R}}{}\operatorname{S\alphaP20\beta(3,11)*** + \DeltaGG}\mp@subsup{}{R}{``` |
| VIII | 44P3p20ß21(11) | 2032 | 3308 | 825** |  |
| IX | 4SP3B20821(11) | 2163 | 3335 | 838 | Calculated; $L_{R} \operatorname{disP}^{2} \beta 20 \beta(11)^{* * *}+$ $\Delta G_{R}{ }^{\text { }}$ |
| X | SaP3 $\beta 20 \beta 21$ (11) | 2228 | 3348 | 842 | Prepared; $\mathbf{3 0} \mathbf{m i n}$ RD $5 \alpha \mathrm{P} 3 \beta 21(11,20)$ |
| XI | 44P20821 $(3,11)$ | 2188 | 3340 | 809** | $\begin{aligned} & \text { Calculated; } L_{R} \Delta 4 \mathrm{P} 20 \beta(3,11)^{\cdots *}+ \\ & \Delta G_{R}^{8} \end{aligned}$ |

[^8]marked, the optimal plateau stretching from 45 to $65 \%$. In all cases, the voiume of $25 \%(w / v) \mathrm{NaOH}$ added to the reaction mixture provided $75 \%$ neutralization ${ }^{5}$. The density of the neutralized reaction mixture being much higher than that of the solvent, a clean centrifugal separation was obtained, but vigorous stirring and several extractions were needed for highest recovery. The volume of benzene used had to be kept at or below $600 \mu \mathrm{l}$, and the total volume below the $1-\mathrm{ml}$ mark to prevent losses due to splashing while stirring with the vortex mixer.

No beneficial effect accrued from working under nitrogen or in complete darkness. ${ }^{5}$

The recoveries listed in Table II were obtained with $10-\mu$ g samples of steroid. A slew decrease down to about half of these values was observed as the amount of steroid was lowered to 50 ng . The $\mathrm{NaBiO}_{3}$ test was still sensitive, however, because the products gave narrow peaks in the early section of the GLC chromatogram. For example, 1 ng of androsterone gave a $50-\mathrm{mm}$ peak at full sensitivity. The sensitivity of the test was lowest with $\Delta 4 \mathrm{~A}(3,17), \Delta 4 \mathrm{~A}(3,11,17)$, and $\Delta 4 \mathrm{~A} 11 \beta(3,17)$ because corresponding peaks had a tendency to flatten and shift upscale at low level ${ }^{1,8}$. Improved sensitivity was obtained in this case by analyzing the $\Delta 4 A 3 \beta 17 \beta$ compounds obtained by RD of the products or the $44 A 3 \beta(17)$ products of the RD-subjected steroids.

TABLE VIII
VALUES OF $L_{R}$ AND $G_{R}$, AND SOURCES OF STEROIDS OF GROUP P11 $1820 \beta 21$

${ }^{*}$ Average $G_{R}$-normal value $=G_{R} P 11 \beta 20 \beta 21=881$.
${ }^{* *} G_{R}$-odd steroid.
*** For $L_{R}$ value, see Table XI of ref. 2.
${ }^{5} \Delta G_{R}=328$; cf. Table XVI.

## $G_{R}$ and $\Delta G_{R}$ data

The $G_{R}$ data in Tables III, IV, VII, and X show that the pattern of $G_{R}$-odd steroids in groups featuring (11) is characteristic and different from the characteristic pattern in groups featuring $11 \beta$ ( $c f$. Tables V, VI, VIII, IX and XII). A comparison with data previously discussed ${ }^{1,2}$ shows that, indeed, the patterns corresponding to (11) and $11 \beta$ are unique.

Table XVI shows $\Delta G_{R}$ values calculated by eqn. 3 for groups listed in column 1 and the groups indicated in rows - from $G_{R}$ values shown between parentheses under group designations. The $\Delta G_{R}$ values listed in the column are the differences between $G_{R}$ values of group pairs to which 226 was added with groups of the androstane series (cf. eqn. 17 of ref. 1).

The mean differences, $\Delta G_{R}$ of $L_{R}$ values for $M$-corresponding $20 \alpha$ and $20 \beta$ isomers, including those previously observed ${ }^{2-4}$, are presented in Table XVII for comparison. Obviously, $\Delta G_{R}$ varies from group to group. While the introduction of (11) or $11 \beta$ exerts an unpredictable influence, it does not affect the reversal in order of

TABLE IX
VALUES OF $L_{R}$ AND $G_{R}$, AND SOURCE OF STEROIDS OF GROUP P11 $120 \propto 21$

| Steroid |  |  |  |  | Source(s) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| M | Abbreviation | $t_{N R}^{\prime}$ | $L_{R}$ | $\boldsymbol{G}^{\text {R }}$ |  |
| I |  | 912 | 2960 | 847 $=$ | $\text { Calculated; } L_{R} 5 \beta \mathrm{P} 11 \beta 20 \alpha^{* *}+$ $A G_{R}{ }^{8}$ |
| $\mathrm{II}^{\text {- }}$ | $5 \alpha \mathrm{P} 11 \beta 20 \alpha 21$ | 1016 | 3007 | 857 | Calculated; $L_{R} 5 \alpha P 11 \beta 20 \alpha^{* * *}+$ $\Delta G_{R}{ }^{5}$ |
| III | $5 \beta$ P3p11 $\beta 20 \alpha 21$ | 1799 | 3255 | 853** | Calculated; $L_{R} 5 \beta \mathrm{P} 3 \beta 11 \beta 20 \alpha^{* * *}+$ $\Delta G_{R}{ }^{5}$ |
| IV | $5 \alpha \mathrm{P} 3 \alpha 11 \beta 20 \alpha 21$ | 1795 | 3254 | $853^{* *}$ | Prepared; 2 h RD SaP3 $\alpha$ 21(11,20); cf. Table I |
| V | $5 \beta \mathrm{P} 11 \beta 20 \alpha 21(3)$ | 1845 | 3266 | 854** | $\begin{aligned} & \text { Calculated; } L_{R} 5 \beta \mathrm{P} 11 \beta 20 \alpha(3)^{* *}+ \\ & \Delta G_{R^{3}} \end{aligned}$ |
| VI | SpP3 $111 \beta 20 \alpha 21$ | 1656 | 3219 | 798** | Prepared; 2 h RD $5 \beta$ P3 $\alpha 21(11,20)$; cf. Table I |
| VII | 5aP11 $\beta 20 \alpha 21$ (3) | 2084 | 3319 | 866 | $\begin{aligned} & \text { Calculated; } L_{R} 5 \alpha \mathrm{P} 11 \beta 20 \alpha(3)^{* *}+ \\ & \Delta G_{R}{ }^{\varepsilon} \end{aligned}$ |
| VIIİ | 44P3F11 $\beta 20 \propto 21$ | 2133 | 3329 | 846** | ```Prepared;2hRD 14P2l(3,11,20)**; cf. Table I``` |
| IX | 45P3p11 $\beta 20 \alpha 21$ | 2270 | 3356 | 859 | Calculated; $L_{R}$ S5P3 $\beta 11 \beta 20 \alpha^{* * *}+$ $A G_{R}{ }^{5}$ |
| X | $5 \alpha \mathrm{P} 3 \beta 11 \beta 20 \alpha 21$ | 2355 | 3372 | 866 | $\begin{array}{rl} \text { Prepared; } 30 \text { min } & \text { RD } \\ & \text { } 5 a \mathrm{P} 3 \beta 21(11,20) ; \\ & \text { cf. Table I } \\ 2 \mathrm{~h} & \mathrm{RD} \\ & \text { } 5 \alpha \mathrm{P} 3 \beta 11 \beta 21(20) ; \\ & c f . \text { Table I } \end{array}$ |
| XI | $\Delta 4 \mathrm{P} 11 \beta 20 \alpha 21(3)$ | 2472 | 3393 | 862 | Calculated; $L_{R} \Delta 4 \mathrm{P} 11 \beta 20 \alpha(3)^{* * *}+$ $\Delta G_{R}{ }^{4}$ |

[^9]appearance of peaks indicated by a negative $\Delta G_{R}$ value for groups which feature 21-OH.

Using eqn. 4, the $L_{R}$ values of steroids listed in column 1 of Table XVIII were calculated, and the errors between calculated and observed values were entered in columns below the designations of the relevant groups. Because only errors obtained from experimental $L_{R}$ values are significant in this test, steroids for which a complete set of significant values was unavailable were not included in column 1. Steroids of particular $M$-configurations, therefore, are not represented by these data. It should be noted, however, that observed $L_{R}$ data on steroids featuring these $M$-configurations and belonging to all groups designated in columns 2-7 of Table XVIII were used in refs. 1 and 2 to demonstrate the validity of eqn. 4 by the same test.

It is evident that very small errors, never exceeding $\pm 3 L_{R}$ units, resulted from the use of eqn. 4 for $L_{R}$ values calculations, except in the case of $5 \beta P 3 \alpha$-steroids, for which the errors were large ${ }^{1,2}$. However, errors observed with the $5 \beta 3 \alpha$-steroids corresponding to columns $2-5$ were so uniform ( $\pm 2$ ) that the following corrections could

TABLE X
VALUES OF $L_{R}$ AND $G_{R}$, AND SOURCES OF STEROIDS OF GROUP P17 $\alpha 20 \beta 21(11)$

| Steroid |  |  |  |  | Source(s) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| M | Abbreviation | $t_{\text {VR }}^{\prime}$ | $L_{\text {R }}$ | $\boldsymbol{G}_{\text {R }}{ }^{*}$ |  |
| I |  | 1167 | 3067 | 956** | Calculated; $L_{R} 5 \beta \mathrm{P} 20 \beta(11)^{* * *}+$ $\Delta G_{R^{3}}$ |
| II | $5 \alpha \mathrm{P} 17 \times 20 \beta 21(11)$ | 1309 | 3117 | 967 | $\begin{aligned} & \text { Calculated; } L_{R} 5 \alpha \mathrm{P} 20 \beta(11)^{\cdots}+ \\ & \Delta G_{R}{ }^{8} \end{aligned}$ |
| III | $5 \beta \mathrm{P} 3 \beta 17 \alpha 20 \beta 21(11)$ | 2339 | 3370 | 969 |  |
| IV | $5 \alpha \mathrm{P} 3 \alpha 17 \alpha 20 \beta 21(11)$ | 2344 | 3370 | 969 | Calculated; $L_{R} 5 \alpha \mathrm{P} 3 \alpha 20 \beta(11)^{* * *}+$ $\Delta G^{k}$ |
| V | 5pP17a20p21 $(3,11)$ | 2275 | 3357 | 945** | Calculated; $L_{R} \operatorname{SPP} \operatorname{PO} \beta(3,11)^{\cdots}+$ $\Delta G_{\mathrm{R}}{ }^{\text { }}$ |
| VI | $5 \beta \mathrm{P} 3 \sim 17 \alpha 20 \beta 21(11)$ | 2218 | 3346 | 925** | P9200; prepared 30 min RD P7100 and P9550 |
| VII | $5 \alpha \mathrm{P} 17 \alpha 20 \beta 21(3,11)$ | 2588 | 3413 | 960** | Calculated; $L_{R} 5 \alpha \mathrm{P} 20 \beta(3,11)^{* * *}+$ $\Delta G_{R}{ }^{s}$ |
| VIII | -4P3F17a20阝21(11) | 2733 | 3436 | 953** | $\begin{aligned} & \text { Prepared; } 30 \mathrm{~min} \mathrm{RD} \\ & 44 \mathrm{P} 17 \alpha 21(3,11,20) \end{aligned}$ |
| IX | A5P3 $\beta 17 \alpha 20 \beta 21(11)$ | 2911 | 3464 | 967 | $\begin{aligned} & \text { Calculated; } L_{R} \Delta S P 3 \beta 20 \beta(11)^{* *}+ \\ & \Delta G_{R^{g}} \end{aligned}$ |
| X | 5 $\alpha$ P3/17 $\alpha 20 \beta 21(11)$ | 3010 | 3478 | 972 | $\begin{aligned} & \text { Prepared; } 30 \min \mathrm{RD} \\ & 5 \alpha \mathrm{P} 3 \beta 17 \alpha 21(11,20) \end{aligned}$ |
| XI | 44P17a20321(3,11) | 2944 | 3469 | 938** | ```Calculated; L_  \DeltaGR}\mp@subsup{}{R}{5``` |

* Average $G_{R}$-normal value $=G_{R} P 17 \alpha 20 \beta 21(11)=969$.
${ }^{* *} G_{R}$-odd steroid.
** For $L_{R}$ value, see Table IX of ref. 2.
\$ $4 G_{R}=457$; cf. Table XVI.
be used successfully: $-28 L_{R}$ units for (11)-featuring steroids, $-27 L_{R}$ units for $11 \beta 20 \beta$-steroids, and -19 with $11 \beta 20 \alpha$-steroids. Thus, at least for these $5 \beta 3 \alpha-$ steroids, the extent of excess oddity ${ }^{1,2}$ also is predictable. Obviously, this is not so for the other $5 \beta 3 \alpha$-steroids. However, samples of $5 \beta 3 \alpha$-steroids are among the most easily obtainable, either as such or by RD of appropriate keto-steroids.

As the above results show, the $L_{R}$ values of heavily substituted steroids can be accurately calculated from the $L_{R}$ value of any less substituted, $M$-corresponding steroid of a related group, and vice versa. These results therefore confirm the principle of constancy of oddity previously enunciated ${ }^{2}$, and the reliability, and versatility of a method of $L_{R}$ value calculation based on eqn. 4. Conversely, this method allows a preliminary determination of structure to be made from retention time data.

Ambiguities that may arise in cases when two or more steroids of different structure have the same, or nearly the same retention time are often dispelled by the TLC data. In our systematic analysis of steroids, TLC is used as a preliminary separation step to obtain several fractions within precisely determined boundaries ${ }^{1}$. Hence, aside from making a subsequent GLC separation of the fraction components possible, this procedure also supplies TLC data on these components which may be decisive in the identification process. The corticosteroids, for example, are found in neatly

TABLE XI
VALUES OF $L_{R}$ AND $G_{R}$, AND SOURCES OF STEROIDS OF GROUP P11 $17 \alpha 20 \beta 21$

| Steroid |  |  |  |  | Source(s) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| M | Abbreviation | $i_{\text {NR }}^{\prime}$ | $L_{\text {R }}$ | $\boldsymbol{G}_{\mathbf{R}}{ }^{*}$ |  |
| I |  | 1327 | 3123 | 1010** | $\begin{aligned} & \text { Calculated; } L_{R} 5 \beta P 11 \beta 20 \beta^{* * *}+ \\ & \Delta G_{R}{ }^{g} \end{aligned}$ |
| II | $5 \alpha \mathrm{P} 11 \beta 17 c 20 \beta 21$ | 1503 | 3177 | 1027 | Calculated; $L_{R} 5 \alpha \operatorname{P11} \beta 20 \beta^{* * *}+$ |
| III |  | 2600 | 3415 | 1013** | P8620 |
| IV | 5 $\alpha$ P $3 \alpha 11 \beta 17 \alpha 20 \beta 21$ | 2630 | 3420 | 1021** | Calculated; $L_{R} 5 \alpha$ P3 $\alpha$ 11 $\beta 20 \beta^{* * * ~}+$ $\Delta G_{R}{ }^{\text { }}$ |
| V | SpP11/17a20ß21(3) | 2679 | 3428 | 1016** | Calculated; $L_{R} 5 \beta \mathrm{P} 11 \beta 20 \beta(3)^{* * *}+$ $\Delta G_{R}{ }^{8}$ |
| VI. | 5 $\beta$ P3 $\alpha 11 \beta 17 \alpha 20 \beta 21$ | 2524 | 3402 | 981** | P8590; prepared 2 h RD P9550 and P7100; cf. Table I |
| VII | 5aP11 $171 \% 20 \beta 21$ (3) | 3076 | 3488 | - 1035 | Calculated; $L_{R} 5 \alpha \mathrm{P} 11 \beta 20 \beta(3)^{* *}+$ $\Delta G_{\mathrm{R}}{ }^{8}$ |
| VIII | $\triangle 4 \mathrm{P} 3 \beta 11 \beta 17 \alpha 20 \beta 21$ | 3182 | 3503 | 1020** | Prepared; 2 h RD Q2500; cf. Table I |
| IX | $\Delta 5 \mathrm{P} 3 \beta 11 \beta 17 \alpha 20 \beta 21$ | 3360 | 3526 | 1029 | Prepared; 2 h RD Q5790; of. Table I |
| X |  | 3472 | 3540 | 1034 | Q4350; prepared 2 h RD P5200; cf. Table 1 |
| XI | 44P11 $\beta 17 \alpha 20 \beta 21$ (3) | 3667 | 3564 | 1033 | Q3790 |

"Average $G_{R}$-normal value $=G_{R}$ P11 $\beta 17 \alpha 20 \beta 21=1032$.
** $G_{R}$-odd steroid.
*** For $L_{R}$ value, see Table XI of ref. 2.
${ }^{5} \Delta G_{R}=478 ; c f$. Table XVI.
TABLE XII
VALUES OF $L_{R}$ AND $G_{R}$, AND SOURCES OF STEROIDS OF GROUP P11 $\beta 17 \alpha 20 \alpha 21$

| Steroid |  |  |  |  | Source(s) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| $\boldsymbol{M}$ | Abbreviation | $t_{\text {NR }}^{\prime}$ | $L_{\text {R }}$ | $G_{R}{ }^{*}$ |  |
| I | 5 $\beta$ P11 $\beta 17 \alpha 20 \alpha 21$ | 1279 | 3107 | 994** | Calculated; $L_{R} 5 \beta \mathrm{P} 11 \beta 20 \alpha^{* * *}+$ $\Delta G_{R^{3}}{ }^{3}$ |
| II | 5 $\alpha$ P11 $\beta_{17 \alpha}$ 20a21 | 1426 | 3154 | 1004 | $\begin{aligned} & \text { Calculated; } L_{R} 5 \alpha \mathrm{P} 11 \beta 20 \alpha^{*=*}+ \\ & \Delta G_{R}{ }^{3} \end{aligned}$ |
| III | $5 \beta P 3 \beta 11 \beta 17 \alpha 20 \alpha 21$ | 2523 | 3402 | 1000** | Calculated; $L_{R} 5 \beta P 3 \beta 11 \beta 20 \alpha^{* * *}+$ |
| IV | $5 \alpha \mathrm{P} 3 \alpha 11 \beta 17 \alpha 20 \alpha 21$ | 2518 | 3401 | 1002** | Calculated; $L_{R} 5 \alpha \mathrm{P} 3 \alpha 11 \beta 20 \alpha^{* * *}+$ |
| V | 5PP11817a20 $211(3)$ | 2588 | 3413 | 1000** |  |
| VI | - $5 \beta \mathrm{P} 3 \sim 11 \beta 17 \alpha 20 \alpha 21$ | 2433 | 3386 | 965** | SRC; prepared 2 h RD P9550 and P7100; cf. Table I |
| VII | SaP11817c20ce21(3) | 2924 | 3466 | 1013 | $\begin{aligned} & \text { Calculated; } L_{R} 5 \alpha \mathrm{P} 11 \beta 20 \alpha(3)^{* * *}+ \\ & \Delta G_{R}{ }^{4} \end{aligned}$ |
| VIII | 44P3F11p17~20a21 | 3000 | 3477 | 994** | Prepared; 2 h RD Q2500; cf. Table I |
| IX |  | 3180 | 3502 | 1005 | Prepared; 2 h RD Q5790; cf. Table I |
| $\mathbf{X}$ | 5aP3p11 $\beta 17 \alpha 20 \alpha 21$ | 3295 | 3518 | 1012 | Prepared; 2 h RD P5200; cf. Table I |
| XI | $\Delta 4 \mathrm{P} 11 \beta 17 \alpha 20 \propto 21(3)$ | 3467 | 3540 | 1009 | Q3760 |

[^10]TABLE XIII
VALUES OF $L_{R}$ AND $G_{R}$, AND SOURCES OF STEROIDS OF GROUP A(I7)*

| Steroid |  |  |  |  | Source(s) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| $\boldsymbol{M}$ | Abbreviation | $r_{\text {NR }}^{\prime}$ | $L_{\text {R }}$ | $G_{\text {R }}{ }^{*}$ |  |
| I | 5阝A(17) | 140.5 | 2148 | 261 | Prepared; cf. ref. 1 |
| II | SaA(17) | 154 | 2187 | 263 | SRC |
| III | -58A3p(17) | 276 | 2441 | 266 | A3670 |
| IV | $5 ¢ A 3 \alpha(17)$ | 275 | 2439 | 264 | A2420 |
| V | $5 \beta \mathrm{~A}(3,17)$ | 279 | 2445 | 261 | A3270 |
| V1 | 5 $\beta$ A3 $\alpha$ (17) | 288.5 | 2460 | 267 | A3610 |
| VII | SaA $(3,17)$ | 309 | 2489 | 261 | A1630 |
| VIII | 44A3 $\beta$ (17) | 331 | 2520 | 263 | Calculated; $M_{R} 44 \mathrm{~A} 3 \beta+\mathrm{G}_{\mathrm{R}}(17)^{* *}$ |
| IX | - 5 A3F (17) | 337 | 2528 | 259 | A8500 |
| $\mathbf{X}$ | $5 \alpha A 3 \beta(17)$ | 348 | 2542 | 263 | A2490 |
| XI | 44A(3,17) | 368 | 2566 | 261 | A8090 |

* Cf. Table IX of ref. 1.
$\because$ Average $G_{R}$-normal value $=G_{R} A(17)=263$.
TABLE XIV
VALUES OF $L_{R}$ AND $G_{R}$, AND SOURCES OF STEROIDS OF GROUP $A_{\text {( }}(11,17)^{*}$

| Steroid |  |  |  |  | Source(s) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| $\boldsymbol{M}$ | Abbreviation | $t_{\text {'ink }}^{\prime}$ | $L_{R}$ | $G_{R}{ }^{* *}$ |  |
| I | 5 $\beta$ A(11,17) | 177 | 2248 | 361 | Prepared* |
| II | $5 \alpha \mathrm{~A}(11,17)$ | 194 | 2287 | 363 | Prepared* |
| III | $5 \beta \mathrm{~A} \beta \beta(11,17)$ | 343 | 2535 | 361 | $\begin{aligned} & \text { Calculated; } M_{R} 5 \beta \mathrm{~A} 3 \beta^{*}+ \\ & G_{R}(11,17)^{* *} \end{aligned}$ |
| IV | $5 \alpha A 3 \alpha(11,17)$ | 342 | 2534 | 359 | A2280 |
| V | $5 \beta \mathrm{~A}(3,11,17)$ | 336 | 2526 | 342*** | A4010 |
| VI | $5 \beta \mathrm{~A} 3 \alpha(11,17)$ | 348 | 2541 | 348*** | A346C |
| VII | 5aA(3,11,17) | 379 | 2578 | 350*** | Prepared* |
| VIII | $\triangle 4 \mathrm{~A} 3 \beta(11,17)$ | 398 | 2599 | $342^{* * *}$ | Calculated* |
| IX | A5A3B(11,17) | 424 | 2627 | 358 | SRC |
| X | $5 \alpha A 3 \beta(11,17)$ | 440 | 2643 | 364 | Prepared* |
| XI | 14A $(3,11,17)$ | 426 | 2629 | 324*** | Calculated * |

*Cf. Table $V$ of ref. 1.
** Average $G_{R}$-normal value $=G_{R} A(11,17)=361$.
** $G_{R}$-odd steroid.
TABLE XV
VALUES OF $L_{R}$ AND $G_{R}$, AND SOURCES OF STEROIDS OF GROUP A11 $\beta(17)^{*}$

| Steroid |  |  |  |  | Source(s) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| M | Abbreviation | $t_{\text {NK }}^{\prime}$ | $\boldsymbol{L}_{R}$ | $G_{R}{ }^{* *}$ |  |
| I | 5BA11 ${ }^{\text {(17) }}$ | 224 | 2350 | 463*** | Prepared* |
| II | $5 \alpha A 11 \beta(17)$ | 251 | 2399 | 475 | Calculated* |
| III | $5 \beta \mathrm{~A} 3 \beta 11 \beta(17)$ | 440 | 2643 | 468*** | Calculated* |
| IV | S $\alpha$ A3 $\alpha 11 \beta(17)$ | 431 | 2634 | 459*** | Al330 |
| $V$ | $5 \beta$ A11 $18(3,17)$ | 441 | 2644 | 460*** | Prepared* |
| VI | $5 \beta$ A3 $\alpha 11 \beta(17)$ | 442 | 2645 | 452*** | A3120 |
| VII | $5 \alpha A 118(3,17)$ | 503 | 2704 | 476 | A2360 |
| VIII | $\triangle 4 \mathrm{~A} 3 \beta 11 \beta(17)$ | 523 | 2720 | 463*** | Calculated* |
| IX | $45 \mathrm{~A} 3 \beta 11 \beta(17)$ | 558 | 2746 | 477 | Calculated* |
| X | SaA3B11 $\beta$ (17) | 571 | - 2757 | 478 | Al500 |
| XI | $\triangle 4 \mathrm{Al1} \beta(3,17)$ | 601 | 2779 | 474 | A6630 |

[^11]table XVI
$\Delta G_{R}$ values*

| Group (a) | Group (b)** |  |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | $\begin{aligned} & A(11) \\ & (150) \end{aligned}$ | $\begin{aligned} & A(11,17) \\ & (361) \end{aligned}$ | $\begin{aligned} & A 17 \beta(11) \\ & (507) \end{aligned}$ | $\begin{aligned} & P(11) \\ & (156) \end{aligned}$ | $\begin{aligned} & P(11,20) \\ & (370) \end{aligned}$ | $\begin{aligned} & \text { P20B(II) } \\ & (5 / 11) \end{aligned}$ | $\begin{aligned} & P 20 \alpha(I I) \\ & (52.3) \end{aligned}$ | $\begin{aligned} & \text { P17 } 1720 \beta(11) \\ & (688) \end{aligned}$ | $\begin{aligned} & \text { P20821(11) } \\ & (839) \end{aligned}$ |  |  |
| P17a20 ${ }^{\text {(11) (654) }}$ | 730 | 519 | 374 | 498 | 283 | 141 | 166 | 654 |  |  |  |
| P17a20a(11) (688) |  |  |  |  |  |  |  |  |  |  |  |
| P20阝21(11)(839) | 917 | 706 | 561 | 685 | 469 | 328 |  | 315 | 130 |  |  |
| P17đ20821(11) (969) | 1046 | 835 | 690 | 814 | 598 | 457 |  |  |  |  |  |
|  | $\begin{aligned} & A 1 / \beta \\ & (222) \end{aligned}$ | $\begin{aligned} & A 11 \beta(17) \\ & (477) \end{aligned}$ | $\begin{aligned} & A_{(568)} 11 \beta 17 \beta \end{aligned}$ | $\begin{aligned} & P 1 / \beta \\ & (222) \end{aligned}$ | $\begin{aligned} & P 1 l \beta(20) \\ & (464) \end{aligned}$ | $\begin{aligned} & \hline \text { PII } 1220 \beta \\ & (555) \end{aligned}$ | $\begin{aligned} & \text { P11820a } \\ & \text { (599) } \end{aligned}$ | $\begin{aligned} & P 1 / \beta 17 \alpha 20 \beta \\ & (723) \end{aligned}$ | $\begin{aligned} & P 11 \beta 20 \beta 21 \\ & (881) \end{aligned}$ | $\begin{aligned} & \text { PllB17 } 120 \alpha \\ & \text { (757) } \end{aligned}$ | $\begin{aligned} & P 11 \beta 20 \alpha 21 \\ & (862) \end{aligned}$ |
| P11P17a20ß (723) | 726 | 472 | 381 | 498 | 257 | 168 | 158 |  |  |  |  |
| P11 $117 \times 20 \alpha$ (757) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| P11 $220 \beta 21$ (881) | 886 | 631 | 542 | 659 | 417 | 328 |  |  |  |  |  |
| P11P20a21 (862) |  |  |  |  |  |  | 262 |  |  |  |  |
| P11 $117020 \beta 21$ (1032) | 1037 | 783 | 690 | 809 | 568 | 478 |  | 308 | 150 | 252 | 147 |
| P11817a20 21 (1007) | 1013 | 758 | 667 | 786 | 545 | 453 | 409 |  |  |  |  |

P11 $\beta(20), \mathrm{P} 20 \beta(11), \mathrm{P} 20 a(11), \mathrm{P} 11 \beta 20 \beta$, and P11 $20 \alpha$, see Tables V-XII of ref. 2, respectively.

TABLE XVII
MEAN DIFFERENCES, $\Delta G_{R}$, OF $L_{R}$ VALUES FOR $M$-CORRESPONDING $20 \alpha$ - AND $20 \beta$ STEROIDS

| Group |  | $\Delta G_{R}{ }^{*}$ | Source |
| :---: | :---: | :---: | :---: |
| P20 $\alpha$ | P20 $\beta$ | +28 | Table XVIII of ref. 2 |
| P20 $\alpha$ (11) | P20 ${ }^{(11)}$ | $\div 13$ |  |
| P11 $\beta^{20 \alpha}$ | P11 $\beta 20 \beta$ | +49 |  |
| P17a20a | P17c20 ${ }^{\text {a }}$ | $+24$ | Table XIV of ref. 4 |
| P20c21 | P20p21 | -23 |  |
| P17020c21 | P17a20821 | -21 |  |
| $\mathrm{P} 17 \times 20 \alpha(11)$ | P17~20p(11) | $+38$ | Calculated from present data; see Tables III-VI, |
| P11 $\beta 17 \alpha 20 \alpha$ | $\mathrm{P} 11 \beta 17 \times 20 \beta$ | $+38$ | VIII and IX, and XI and XII |
| P11 $120 \alpha 21$ | P11 ${ }^{1} 20821$ | -18 |  |
| P11\%17a20 21 | P11817a20ß21 | -20 |  |

* $\Delta G_{R}$ is expressed in $L_{R}$ units. For specific $M$-configurations, the deviation from the mean $\Delta G_{R}$ value, $\varepsilon$ (cf. Table XVIII of ref. 2) should be added to $G_{R}$. The only exception to this rule is the large $\Delta G_{\mathrm{R}},+55$, for $5 \beta \mathrm{P} 3 \alpha 11 \beta 17 \alpha 20 \alpha$ and $5 \beta \mathrm{P} 3 \alpha 11 \beta 17 \alpha 20 \beta$ (cf. Tables XI and XII).
separated TLC fractions in order of decreasing polarity, as shown by the corresponding $R_{b}$ values of $\Delta 4 \mathrm{P}$-corticosteroids in brackets:
$\triangle 4 \mathrm{P} 11 \beta 17 \alpha 21(3,20)$, cortisol [0.142]
$\triangle 4 \mathrm{P} 17 \alpha 21(3,11,20)$, cortisone [0.300]
$\Delta 4 \mathrm{PI} 1 \beta 21(3,20)$, corticosterone [0.388]
$\triangle 4 \mathrm{P} 17 \alpha 21(3,20)$, cortexolone [ 0.468 ]
$\Delta 4 \mathrm{P} 21(3,11,20)$, dehydrocorticosterone [0.660]
44P21 (3,20), cortexone [0.832]
Further decisive structural information is gained by the application of appropriate discriminatory tests based on the use of reactions described in the present series. Such tests are very sensitive, often requiring less material than is needed to produce high-resolution mass spectra for positive identification and, therefore, requiring less extensive and time-consuming preparative effort. While this advantage is appreciable when dealing with the very low steroid levels found in animal blood and tissues, the operating costs of the method are also much lower ${ }^{2}$. Last, but not least, the method does not require samples of standard steroid for comparison because both the preliminary and the final identification can be made directly from predictable TLC and GLC properties. Hence, with this method, the current unavailability of many steroid standards no longer constitutes a serious obstacle to the systematic analysis of these compounds.

The simplicity of the method contrasts with the complexity of the present, extensive investigation on which it is based. This is evident, for example, from the essential GLC requirements for its effective application, namely: (1) a strict adherence to the type of non-polar column and conditions selected, including the use of two internal standards ${ }^{1}$ and (2) standardization of the column, i.e., determination of $\Delta G_{R}$ values from readily available steroid standards by rapid, systematic procedures as described in ref. 1.
TABLE XVIII
ERROR* ON $L_{R}$ VALUES CALCULATED BY THE A $G_{R}$ METHOD"* FOR STEROIDS OF GROUPS*" P17 $20 \beta 21(11)$, PI1 $\beta 17 \alpha 20 \beta 21$, AND P11 $\beta 17 \alpha 20 \alpha 21$

| Steroid | Error on $L_{R}$ values |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | A(11) | A(11,17) | P(1!) | P(11,20) | A17B(11) | P20B( 11 ) | P17C20月(1]) | P20¢21(11) |
| 5ßP3a17 $20 \beta 21$ (11) | $+26$ | +30 | $+30$ | +28 | $+15$ | $+17$ | $+16$ | -4 |
| $\triangle 4 \mathrm{P} 317 \times 20 \beta 21(11)$ | 0 | -2 | $+1$ | $-1$ | 0 | $+1$ | 0 | +2 |
| $5 \alpha \mathrm{P} 3 \mathrm{\beta} 17 \mathrm{C} 20 \beta 21(11)$ | $-1$ | 0 | $-1$ | -2 | $-1$ | $-1$ | $+2$ | 0 |
|  | A/1P | $A 11 \beta(17)$ | P/l ${ }^{\text {P }}$ | $P 1 / \beta(20)$ | A11/ $17 \%$ | P119208 | P11817420ß | PlIP20821 |
| 5 1 P3 $311 / \beta 17 \alpha 20 \beta 21$ | +27 | +26 | $+29$ | +25 | $+2$ | +14 | +2 | -5 |
| $\triangle 4 \mathrm{P} 3 \beta 11 \beta 17 \alpha 20 \beta 21$ | $-1$ | 0 | -2 | -2 | -2 | 0 | -2 | 0 |
| $\triangle 5 \mathrm{P} 3 \beta 11 \beta 17 \alpha 20 \beta 21$ | $+2$ | $+3$ | $+1$ | +1 | $+1$ | $+2$ | $+1$ | $+2$ |
| $5 \alpha \mathrm{P} 3 \beta 11 \beta 17 \alpha 20 \beta 21$ | $+1$ | 0 | $+1$ | 0 | 0 | $+2$ | -1 | $+1$ |
|  | $A I / \beta$ | $A 11 \beta(17)$ | P1/3 | $P \\| P(20)$ | Al1317\% | P1/820a | P11817a20ca | PlıP20a2l |
| 5 $\beta$ P3 $\alpha 11 \beta 17 \alpha 20 \alpha 21$ | +19 | $+17$ | $+22$ | +18 | $-5$ | $+15$ | $+17$ | -20 |
| $\triangle 4 \mathrm{P} 3 \beta 11 \beta 17 \alpha 20 \alpha 21$ | +1 | +1 | $+1$ | +1 | +1. | 0 | $+1$ | $-1$ |
| $\triangle 5 \mathrm{P} 3 \beta 11 \beta 17 \alpha 20 \alpha 21$ | +2 | +2 | $+2$ | $+2$ | $+2$ | $+1$ | $+1$ | $+1$ |
| 54 P 3 P11 $1817 \alpha 20 \alpha 21$ | $-1$ | $-3$ | 0 | $-1$ | $-1$ | $-2$ | $-1$ | $+1$ |
| $\triangle 4 \mathrm{P} 11 \beta 17 \sim 20 \mu 21(3)$ | -2 | $-3$ | $-3$ | $-2$ | - 3 | $-1$ | 0 | 0 |

[^12]By ensuring an excellent reproducibility and reliability of $L_{R}$ data, the refined techniques which help to meet the first requirement also considerably reduce the amount of work required for effective operation. Once acquired, $L_{R}$ and $\Delta G_{R}$ values constitute a set of permanent, reliable constants characteristic of the system

## ACKNOWLEDGEMENTS

We are grateful to Dr. D. F. Johnson, National Institute of Health, Bethesda, Md., U.S.A., and to Professor W. Klyne and Dr. D. N. Kirk of Westfield College, London, Great Britain, for numerous samples from the Steroid Reference Collection.

## REFERENCES

1 F. A. Vandenheuvel, J. Chromatogr., 96 (1974) 47.
2 F. A. Vandenheuvel, J. Chromatogr., 103 (1975) 113.
3 F. A. Vandenheuvel, J. Chromatogr,, 105 (1975) 359.
4 F. A. Vandenheuvel, J. Chromatogr., 115 (1975) 161.
5 C. J. W. Brooks and J. K. Norymberski, Biochem. J., 55 (1953) 371.
6 W. Nowaczinski, M. Goldner, J. Genest, P. Mavraux and L. Langevin, J. Lab. Clin. Med., 45 (1955) 818.

7 H. Breuer and L. Nocke, Z. Vitam. Horm. Fermentforsch., 9 (1957) 28.
8 F. A. Vandenheuvel and A. S. Court, J. Chromatogr., 39 (1969) 1.


[^0]:    * Contribution No. 656 of the Animal Research Institute.

[^1]:    * In the tables, under source, a letter followed by four digits indicates the catalogue number of Steraloids Inc., P.O. Box 127, Pawling, N.Y. 12564, U.S.A. Steroids provided by the Steroid Standard Collection are indicated by SRC; see Acknowledgements.

[^2]:    * While the RD of (20) invariably produces both $20 \alpha$ and $20 \beta$ isomers, that of (3) yields almost exclusively $3 \alpha$ with a $5 \beta$ compound and $3 \beta$ with a $5 \alpha$ compound. For 30 -min reductions leading to compounds still featuring (11), cf. text.

    As always ${ }^{1-3}$, the 3 -keto group in $5 \beta \mathrm{P}(3)$-steroids was converted to $3 \alpha$ and to $3 \beta$ in all others. The 11 -keto group yielded $11 \beta$ exclusively after 2 h reduction ${ }^{1,2}$. After 30 min, only a fraction of (11) was reduced, while (20) was completely reduced to $20 \alpha$ and $20 \beta^{1,2}$. The preparation of (11)-steroids completely reduced in the side-chain was therefore possible (see Tables III, IV, VII, and X).

[^3]:    * All starting materials listed were available from outside sources; prepared compounds were also used (ef. text).
    ** The $L_{R}$ values of most products are listed in Tables XIII-XV.

[^4]:    * Average $G_{R}$-normal value $=G_{R} P 17 \alpha 20 \beta(11)=654$.
    * $G_{R}$-odd steroid.
    ** For $L_{R}$ value, see Table IX of ref. 2.
    ${ }^{3} \Delta G_{R}=141$; cf. Table XVI.

[^5]:    * Average $G_{R}$-normal value $=G_{R} P 17 \alpha 20 \alpha(11)=688$.
    ** $G_{R}$-odd steroid.
    ** For $L_{R}$ value, see Table $X$ of ref. 2.
    ${ }^{5} \Delta G_{R}=166 ; c f$. Table XVI.

[^6]:    ${ }^{\text {z }}$ Average $G_{R}$-normal value $=G_{R}$ P11 $\beta 17 \alpha 20 \beta=723$.
    ** $G_{R}$-odd steroid.
    *** For $L_{R}$ value, see Table XI of ref. 2.
    ${ }^{{ }^{5}} \Delta G_{R}=168 ; c f$. Table XVI.

[^7]:    ${ }^{*}$ Average $G_{R}$-normal value $=G_{R} P 11 \beta 17 \omega 20 \alpha=757$.
    ${ }^{*} G_{R}$-odd steroid.
    *** For $L_{R}$ value, see Table XII of ref. 2.
    ${ }^{5} \Delta G_{R}=158, c f$. Table XVI.

[^8]:    * Average $G_{R}$-normal value $=G_{R} \mathbf{P 2 0 \beta 2 1 ( 1 1 )}=839$.
    ${ }^{* *} G_{R}$-odd steroid.
    ** For $L_{R}$ value, see Table IX of ref. 2.
    ${ }^{*} A G_{R}=328 ; c f$. Table XVI.

[^9]:    * Average $G_{R}$-normal value $=G_{R}$ P11 $120 \alpha 21=862$.
    ${ }^{* *} G_{R}$-odd steroid.
    $\therefore$ For $L_{R}$ value, see Table XII of ref. 2.
    ${ }^{8} \Delta G_{R}=262 ; c f$. Table XVI.

[^10]:    * Average $G_{R}$-normal value $=G_{R} P 11 \beta 17 \alpha 20 \alpha 21=1007$.
    ${ }^{* *} G_{R}$-odd steroid.
    *** For $L_{R}$ value, see Table XII of ref. 2.
    ${ }^{*} A G_{R}=409 ;$ of. Table XVI.

[^11]:    - CE Table vit ref. i.
    
    $=E G_{R}$ ode steroid.

[^12]:    "* $L_{R}$ values calculated as $L_{R}(\mathrm{a})=L_{R}(\mathrm{~b})+\Delta G_{R}$ (eqn. 15 of ref. 1), where $L_{R}(\mathrm{~b})$ is the $L_{R}$ value of the $M$-corresponding steroid in the related group
    indicated in the row, and $A G_{R}$ is the appropriate value taken from Table XVI. $L_{R}$ values of steroids of groups $\mathrm{A}(11,17)$ and A11 $\beta(\mathrm{I})$ are listed in Tables XIV and XV, respectively. $L_{R}$ values of steroids of groups P17a20 111 ), P11 $\beta 17 \alpha 20 \beta, \mathrm{P} 11 \beta 17 \alpha 20 \alpha, \mathrm{P} 20 \beta 21(11), \mathrm{P} 11 \beta 20 \beta 21$, and $\mathrm{P} 11 \beta 20 \alpha 21$ are listed in Tables III-IX, respectively. For $L_{R}$ values of steroids of groups $A(11), A 11 \beta, A 17 \beta(11)$, and $A 11 \beta 17 \beta$, see Tables III, IV, VII, and VIII of ref. 1 , respectively. For $L_{R}$ values of steroids of groups $P(11), P 11 \beta, P(11,20), \mathrm{P} 11 \beta(20), \mathrm{P} 20 \beta(11), \mathrm{P} 11 \beta 20 \beta$, and $\mathrm{P} 11 \beta 20 \alpha$, see Tables V, VI, VII, VIII, $1 \mathrm{X}, \mathrm{XII}$, and XII of ref. 2 , respectively.
    ${ }^{* * *} L_{K}$ values of steroids of these groups are listed in Tables X, XI, and XII, respectively.

